Evidence map›Paper›PMID 35959371›Full record

ArticleFrontiers in cellular and infection microbiology2022

ORFV infection enhances CXCL16 secretion and causes oncolysis of lung cancer cells through immunogenic apoptosis.

Ruixue Wang, Jingying Mo, Xiaoshan Luo, Guixian Zhang, Fang Liu, Shuhong Luo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Programmed cell death in lung cancer: mechanisms, immune responses, and therapeutics.Apoptosis : an international journal on programmed cell death · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ruixue WangDepartment of Basic Medical Sciences, School of Medicine, Foshan University, Foshan, China.
Jingying MoDepartment of Laboratory Medicine, School of Medicine, Foshan University, Foshan, China.
Xiaoshan LuoDepartment of Laboratory Medicine, School of Medicine, Foshan University, Foshan, China.
Guixian ZhangDepartment of Basic Medical Sciences, School of Medicine, Foshan University, Foshan, China.
Fang LiuDepartment of Basic Medical Sciences, School of Medicine, Foshan University, Foshan, China.
Shuhong LuoDepartment of Laboratory Medicine, School of Medicine, Foshan University, Foshan, China.
Foshan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic viruses have been emerging as a promising therapeutic option for cancer patients, including lung cancer. Orf virus (ORFV), a DNA parapoxvirus, can infect its natural ungulate hosts and transmit into humans. Moreover, the ORFV has advantages of low toxicity, high targeted, self-amplification and can induce potent Th1-like immunity. This study explored the therapeutic potential of ORFV infection for human lung cancer therapy and investigated the molecular mechanisms. We used a previously described ORFV NA1/11 strain and tested the oncolysis of ORFV NA1/11 in two lines of lung cancer cells

Indexed as

Ecthyma, ContagiousLung NeoplasmsOrf virusAnimalsApoptosisChemokine CXCL16HumansLungSheepChemokine CXCL16CXCL16 protein, humanapoptosisCXCL16immunogenic cell death (ICD)lung cancerOrf virus (ORFV)

Identifiers

PMID35959371
PMCPMC9358046
OpenAlexW4287219213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.